Lupin Rolls Out Spiriva Generic In US, Looks To Take Back From Respimat

Indian Firm Bagged First FDA Approval For Tiotropium DPI In June

Indian respiratory player Lupin has begun shipping its US generic version of Boehringer Ingelheim’s Spiriva HandiHaler, amid plans both to capture share from the originator’s follow-on soft mist inhalation brand and continue development of its own Respimat rival product.

COPD awareness frame poster with lungs filled with air bubbles on red background. Chronic obstructive pulmonary disease symbol. Medical template for clinics and centers. Vector illustration.
• Source: Shutterstock

Lupin has followed through with its launch of the first generic version of Boehringer Ingelheim’s Spiriva HandiHaler (tiotropium bromide inhalation powder) 18 mcg/capsule in the US, positioning itself to capture share from a market worth north of $1.2bn.

Approved in June as the first dry powder inhaler approval from India for the US market, Lupin’s generic is indicated for the treatment of chronic obstructive pulmonary

More from Products

More from Generics Bulletin